drugset
drugset / Trial / NCT00646165

Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

NCT00646165 ↗

Phase 1 Terminated 1 enrolled Mundipharma Research Limited
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the dose and duration of treatment for the best overall response with Forodesine in relapsed B-cell chronic lymphocytic leukemia

Timeline

Start
2008-07
Primary completion
2009-01
Completion
2009-05

Outcome

Outcome not reported

Stopped (Enrollment): “Poor recruitment and change in development strategy”

Drugs

EvaluationDrugModalityDoseRoute
Subject forodesine Small molecule — —

Indications

B-cell chronic lymphocytic leukemia